Investigating how a specific protein affects fibrosis in systemic sclerosis
Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic Sclerosis
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-11083751
This study is looking at how a specific protein called IRF7 affects the immune system and scarring in people with systemic sclerosis, with the goal of finding new ways to treat this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11083751 on ClinicalTrials.gov |
What this research studies
This research focuses on systemic sclerosis, a serious autoimmune disease that leads to excessive fibrosis, or scarring, in various tissues. The team aims to understand the role of interferon regulatory factor 7 (IRF7) in the disease process, particularly how it connects immune system dysfunction to fibroblast activity, which contributes to fibrosis. By analyzing gene expression and using advanced techniques, the researchers hope to uncover new insights into the mechanisms driving this condition, potentially leading to better therapeutic strategies. The study involves both laboratory experiments and analysis of patient samples to explore these connections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic sclerosis who are experiencing significant symptoms related to fibrosis.
Not a fit: Patients with other autoimmune diseases that do not involve fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce fibrosis and improve outcomes for patients with systemic sclerosis.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune dysregulation in fibrosis, suggesting that this approach could yield valuable insights.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ASSASSI, SHERVIN — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: ASSASSI, SHERVIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease